AllSci News
Novo signs up for Orbis macrocycle platform in USD 1.4b deal
Copenhagen-based Orbis Medicines has entered a multi-target drug discovery collaboration and license agreement with Novo Nordisk (NYSE: NVO) worth up to USD...
Acelot takes TDP-43 ALS drug ACE-2223 into first-in-human trial
South San Francisco-based Acelot has dosed the first healthy volunteer in a Phase Ia clinical trial of ACE-2223, an orally bioavailable small molecule...
FDA expands Bayer’s Kerendia to type 1 diabetes-associated chronic kidney disease
The US FDA has approved Kerendia (finerenone) for a third indication: reducing urinary albumin-to-creatinine ratio (UACR), which is expected to slow...
Sling secures USD 123m to advance oral TED drug linsitinib
Ann Arbor, Michigan-based Sling Therapeutics has raised USD 123 million in a Series C financing to fund the Phase III pivotal trial of linsitinib (OSI-906),...
Weill Cornell wins USD 2.1m NIH grant to advance on-demand male contraceptive into Phase I
Weill Medical College of Cornell University has received a USD 2.07 million NIH center grant to advance a nonhormonal, on-demand male contraceptive...
Roche’s Lunsumio combination hits Phase III PFS goal in 2L+ follicular lymphoma
Roche's (SIX: RO, ROP; OTCQX: RHHBY) reported that the Phase III CELESTIMO study of mosunetuzumab (Lunsumio) in combination with lenalidomide met its...
SK Bio licenses Parkinson’s candidate 1ST-104 in USD 314.8m deal
South Korea-based SK Biopharmaceuticals Co., Ltd. (KRX: 326030) has licensed exclusive global rights to 1ST-104, a preclinical oral small-molecule dual...
Akeso’s EGFR/TROP2 bispecific ADC cleared for Phase I testing in China
AK158D1, a bispecific antibody-drug conjugate (ADC) simultaneously targeting epidermal growth factor receptor (EGFR) and trophoblast cell surface antigen 2...
UPenn study identifies NSD2–SETD2–EZH2 axis in KRAS lung cancer immunity
Researchers at the University of Pennsylvania have identified an antagonistic relationship among three histone methyltransferases — NSD2, SETD2, and EZH2 —...
Escugen, Sovran pivot into co-development of pan-tumor bispecific MICA/B ADC
Shanghai Escugen Biotechnology Co., Ltd. and Woodinville, Washington-based Sovran Bio, Inc. have expanded their collaboration into a co-development...
Novo expands AI drug discovery push with Anthropic’s Claude Science collaboration
Novo Nordisk (Copenhagen: NOVO B) and Anthropic have announced a research collaboration that will deploy Anthropic's Claude Science platform and frontier AI...
Circle Pharma raises USD 92.5m in Series E for cyclin D inhibitor
South San Francisco-based Circle Pharma, Inc. has raised USD 92.5 million in an oversubscribed Series E financing to advance its lead cyclin D1 inhibitor...
Stanford builds mice with human cortical tissue to model brain development
A Stanford University team has developed a mouse model in which transplanted human cortical organoids expand to occupy most of the available cortical...
Skyhawk’s SKY-0515 shows 1.59-point cUHDRS advantage at 15 months in Huntington’s disease
Boston-based Skyhawk Therapeutics, Inc. reported final Phase I/II data for SKY-0515 in Huntington's disease, with treated patients showing a statistically...
Cambium Bio secures AUD 10.85m for Phase III of topical dry eye biologic
Australia-based Cambium Bio Limited (ASX: CMB) announced a combined AUD 10.85 million funding package to initiate its pivotal Phase III trial of Elate...
The AllSci Brief
Free, systematic R&D and deal news. Daily.